Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001564590-20-054025
Filing Date
2020-11-16
Accepted
2020-11-16 08:00:54
Documents
58
Period of Report
2020-09-30

Document Format Files

Seq Description Document Type Size
1 10-Q rapt-10q_20200930.htm 10-Q 2256669
2 EX-31.1 rapt-ex311_7.htm EX-31.1 16550
3 EX-31.2 rapt-ex312_6.htm EX-31.2 16517
4 EX-32.1 rapt-ex321_8.htm EX-32.1 14706
  Complete submission text file 0001564590-20-054025.txt   5783451

Data Files

Seq Description Document Type Size
5 XBRL INSTANCE DOCUMENT rapt-20200930.xml EX-101.INS 962069
6 XBRL TAXONOMY EXTENSION SCHEMA rapt-20200930.xsd EX-101.SCH 41794
7 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE rapt-20200930_cal.xml EX-101.CAL 37790
8 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE rapt-20200930_def.xml EX-101.DEF 129329
9 XBRL TAXONOMY EXTENSION LABEL LINKBASE rapt-20200930_lab.xml EX-101.LAB 328406
10 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE rapt-20200930_pre.xml EX-101.PRE 241008
Mailing Address 561 ECCLES AVENUE SOUTH SAN FRANCISCO CA 94080
Business Address 561 ECCLES AVENUE SOUTH SAN FRANCISCO CA 94080 (650) 489-9000
RAPT Therapeutics, Inc. (Filer) CIK: 0001673772 (see all company filings)

EIN.: 473313701 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-38997 | Film No.: 201313746
SIC: 2834 Pharmaceutical Preparations